BCL2 and breast carcinoma: TMP and the prescriptions can also reverse multidrug resistance induced by Dox in breast cancer, bladder cancer, hepatocellular carcinoma through regulating the expression and function of P-gp, MRP2, MRP3, MRP5, MRP1, GST, Bcl-2, and TOPO-II, or directly enhance the anti-cancer effect of Dox [55–58].